[Ivabradine for Treatment of Heart Failure with Preserved Ejection Fraction]
| Autor: | G V Babushkina, G I Shaikhlislamova |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
030204 cardiovascular system & hematology Ventricular Function Left 03 medical and health sciences 0302 clinical medicine Heart Rate Internal medicine medicine Humans Ivabradine 030212 general & internal medicine Myocardial infarction Prospective Studies Aged Heart Failure Ejection fraction business.industry Lisinopril Stroke Volume Benzazepines Middle Aged medicine.disease Treatment Outcome Valsartan Bisoprolol Heart failure Cardiology Quality of Life Cardiology and Cardiovascular Medicine business Heart failure with preserved ejection fraction medicine.drug |
| Zdroj: | Kardiologiia. 60(10) |
| ISSN: | 0022-9040 |
| Popis: | Aim To evaluate the effect of combination ivabradine-containing therapy for chronic heart failure (CHF) with preserved ejection fraction on quality of life (QoL) and the primary composite endpoint during a one-year follow-up.Material and methods This study included 160 patients aged 45 to 65 years with NYHA functional class (FC) II-III CHF with preserved left ventricular ejection fraction (CHF-PEF) and grade I and II diastolic dysfunction associated with FC III stable angina with sinus rhythm and a heart rate (HR) higher than 70 bpm. Presence of CHF-PEF was confirmed by results of echocardiography and myocardial tissue Doppler imaging. During one year of prospective observation, effects of bisoprolol and ivabradine as a part of the combination therapy on the primary composite endpoint, including death from cardiovascular complications (CVC) and hospitalizations for myocardial infarction (MI) or CHF, were evaluated in patients with CHF-PEF. Patients were randomized to three groups: A, bisoprolol with dose titration from 2.5 to 10 mg; В, combination of bisoprolol 2.5-10 mg and ivabradine 10-15 mg/day; and С, ivabradine 10-15 mg/day. All patients were on a chronic background therapy, including angiotensin-converting enzyme inhibitors (lisinopril) or, if not tolerated, angiotensin II receptor blockers (valsartan), antiaggregants, statins (atorvastatin, rosuvastatin), and short-acting nitrates as required. If edema developed diuretics were added. The follow-up duration was one year.Results After 12 weeks of follow-up, the achievement of goal HR in group A was associated with a tendency to increased distance in the 6-min walk test from 279±19 to 341±21 m (р>0,05); in group B the distance increased from 243±25 to 319±29 m (рConclusion The inclusion of bisoprolol and ivabradine into the background therapy of CHF-PEF patients with stable IHD provided an improvement of QoL and a decrease in the risk of hospitalization for acute MI and CHF during the year of observation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|